RAD21

Across TCGA pan-cancer cohorts, RAD21 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated RAD21 data layer compared with 26 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher RAD21 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated RAD21 expression acts as an unfavorable survival marker, although some lineages such as LUAD and LSCC show a favorable association.

LUAD, HNSC, and LSCC are the cancer types where RAD21 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Tertile	III,IV	0.848	0.317	.001	32	view →
HNSC	OS	Median	All	0.798	0.906	.005	20	view →
LSCC	DFS	Quartile	II,III,IV	0.867	0.435	.019	5	view →
CCRCC	DFS	Tertile	III,IV	1.000	0.351	.036	1	view →
PDAC	DFS	Median	II,III,IV	0.819	0.687	.037	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

RAD21–LUAD (OS)

Open the LUAD breakdown →